www.active-investors.com/registration-sg

The S&P/TSX Composite Index lost 6.90 points, or 0.04%, to close Wednesday's trading session at 15,908.78. The TSX Venture Exchange shaved off 0.28 points, or 0.04%, to finish at 783.66.

Moreover, the Healthcare index was down by 1.89%, closing at 77.22.

Today's stocks of interest consist of: OrganiGram Holdings Inc. (TSXV: OGI), IntelGenx Technologies Corporation (TSXV: IGX), Antibe Therapeutics Inc. (TSXV: ATE), and Emerald Health Therapeutics Inc. (TSXV: EMH). Click the link below to view a sample of the free research report that will be available to you as a member of Active-Investors:

www.active-investors.com/registration-sg

OrganiGram Holdings Inc.

Moncton, Canada-based OrganiGram Holdings Inc.'s stock gained 11.70%, to finish Wednesday's session at $3.82 with a total volume of 6.52 million shares traded. Over the last one month and the previous three months, OrganiGram's shares have surged 23.62% and 73.64%, respectively. Furthermore, the stock has gained 17.54% in the past one year. Shares of the Company, which through its subsidiary, Organigram Inc., produces and sells medical marijuana in Canada, are trading above its 50-day and 200-day moving averages. OrganiGram Holdings' 50-day moving average of $3.22 is above its 200-day moving average of $2.61. View the research report on OGI.V at:

www.active-investors.com/registration-sg/?symbol=OGI

IntelGenx Technologies Corp.

On Wednesday, shares in Saint-Laurent, Canada headquartered IntelGenx Technologies Corp. recorded a trading volume of 81,325 shares, which was higher than their three months average volume of 16,984 shares. The stock ended the day 6.74% lower at $0.83. Shares of the Company, which develops novel oral immediate-release and controlled-release products for the pharmaceutical market, are trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $0.99 is above its 50-day moving average of $0.93. Get the free report on IGX.V at:

www.active-investors.com/registration-sg/?symbol=IGX

Antibe Therapeutics Inc.

On Wednesday, shares in Toronto, Canada headquartered Antibe Therapeutics Inc. ended the session 6.25% lower at $0.15 with a total volume of 516,515 shares traded. Antibe Therapeutics' shares have surged 57.89% in the last one month and 66.67% in the previous three months. Shares of the Company, which together with its subsidiaries, originates, develops, and out-licenses patent protected pharmaceuticals primarily in Canada, Europe, and the US, are trading above its 50-day and 200-day moving averages. Furthermore, the stock's 50-day moving average of $0.10 is greater than its 200-day moving average of $0.09. Access the most recent report coverage on ATE.V at:

www.active-investors.com/registration-sg/?symbol=ATE

Emerald Health Therapeutics Inc.

Victoria, Canada headquartered Emerald Health Therapeutics Inc.'s stock closed the day 10.66% higher at $4.05. The stock recorded a trading volume of 6.84 million shares, which was above its three months average volume of 993,565 shares. Emerald Health Therapeutics' shares have rallied 135.47% in the last one month, 258.41% in the past three months, and 251.92% in the previous one year. Shares of the Company, which together with its subsidiaries, produces and sells medical marihuana and cannabis oils in Canada, are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $2.09 is greater than its 200-day moving average of $1.62. Today's complimentary report on EMH.V can be accessed at:

www.active-investors.com/registration-sg/?symbol=EMH

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 483772

"/> Research Reports on OrganiGram Holdings, IntelGenx Technologies, Antibe Therapeutics, and Emerald Health Therapeutics « MarketersMedia – Press Release Distribution Services – News Release Distribution Services
MarketersMEDIA Year End Sale is Finally Back! Get up to 70% OFF on your press releases. Hurry! Limited time only.
Click Here
How It Works? Plans & Pricing Our Distributions Newsroom Info Hub Sign Up Sign In Send Press Release Contact Sales
Contact Sales Sign Up Your Account Send Press Release
MarketersMEDIA / Newsroom / Research Reports on OrganiGram Holdings, IntelGenx Technologies, Antibe Therapeutics, and Emerald Health Therapeutics

Research Reports on OrganiGram Holdings, IntelGenx Technologies, Antibe Therapeutics, and Emerald Health Therapeutics

Share This Press Release

LONDON, UK / ACCESSWIRE / December 07, 2017 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: OrganiGram Holdings, IntelGenx Technologies, Antibe Therapeutics, and Emerald Health Therapeutics. Access our complimentary up-to-the-minute research reports by becoming an online member now:

www.active-investors.com/registration-sg

The S&P/TSX Composite Index lost 6.90 points, or 0.04%, to close Wednesday's trading session at 15,908.78. The TSX Venture Exchange shaved off 0.28 points, or 0.04%, to finish at 783.66.

Moreover, the Healthcare index was down by 1.89%, closing at 77.22.

Today's stocks of interest consist of: OrganiGram Holdings Inc. (TSXV: OGI), IntelGenx Technologies Corporation (TSXV: IGX), Antibe Therapeutics Inc. (TSXV: ATE), and Emerald Health Therapeutics Inc. (TSXV: EMH). Click the link below to view a sample of the free research report that will be available to you as a member of Active-Investors:

www.active-investors.com/registration-sg

OrganiGram Holdings Inc.

Moncton, Canada-based OrganiGram Holdings Inc.'s stock gained 11.70%, to finish Wednesday's session at $3.82 with a total volume of 6.52 million shares traded. Over the last one month and the previous three months, OrganiGram's shares have surged 23.62% and 73.64%, respectively. Furthermore, the stock has gained 17.54% in the past one year. Shares of the Company, which through its subsidiary, Organigram Inc., produces and sells medical marijuana in Canada, are trading above its 50-day and 200-day moving averages. OrganiGram Holdings' 50-day moving average of $3.22 is above its 200-day moving average of $2.61. View the research report on OGI.V at:

www.active-investors.com/registration-sg/?symbol=OGI

IntelGenx Technologies Corp.

On Wednesday, shares in Saint-Laurent, Canada headquartered IntelGenx Technologies Corp. recorded a trading volume of 81,325 shares, which was higher than their three months average volume of 16,984 shares. The stock ended the day 6.74% lower at $0.83. Shares of the Company, which develops novel oral immediate-release and controlled-release products for the pharmaceutical market, are trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $0.99 is above its 50-day moving average of $0.93. Get the free report on IGX.V at:

www.active-investors.com/registration-sg/?symbol=IGX

Antibe Therapeutics Inc.

On Wednesday, shares in Toronto, Canada headquartered Antibe Therapeutics Inc. ended the session 6.25% lower at $0.15 with a total volume of 516,515 shares traded. Antibe Therapeutics' shares have surged 57.89% in the last one month and 66.67% in the previous three months. Shares of the Company, which together with its subsidiaries, originates, develops, and out-licenses patent protected pharmaceuticals primarily in Canada, Europe, and the US, are trading above its 50-day and 200-day moving averages. Furthermore, the stock's 50-day moving average of $0.10 is greater than its 200-day moving average of $0.09. Access the most recent report coverage on ATE.V at:

www.active-investors.com/registration-sg/?symbol=ATE

Emerald Health Therapeutics Inc.

Victoria, Canada headquartered Emerald Health Therapeutics Inc.'s stock closed the day 10.66% higher at $4.05. The stock recorded a trading volume of 6.84 million shares, which was above its three months average volume of 993,565 shares. Emerald Health Therapeutics' shares have rallied 135.47% in the last one month, 258.41% in the past three months, and 251.92% in the previous one year. Shares of the Company, which together with its subsidiaries, produces and sells medical marihuana and cannabis oils in Canada, are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $2.09 is greater than its 200-day moving average of $1.62. Today's complimentary report on EMH.V can be accessed at:

www.active-investors.com/registration-sg/?symbol=EMH

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 483772

LONDON, UK / ACCESSWIRE / December 07, 2017 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: OrganiGram Holdings, IntelGenx Technologies, Antibe Therapeutics, and Emerald Health Therapeutics. Access our complimentary up-to-the-minute research reports by becoming an online member now:

www.active-investors.com/registration-sg

The S&P/TSX Composite Index lost 6.90 points, or 0.04%, to close Wednesday's trading session at 15,908.78. The TSX Venture Exchange shaved off 0.28 points, or 0.04%, to finish at 783.66.

Moreover, the Healthcare index was down by 1.89%, closing at 77.22.

Today's stocks of interest consist of: OrganiGram Holdings Inc. (TSXV: OGI), IntelGenx Technologies Corporation (TSXV: IGX), Antibe Therapeutics Inc. (TSXV: ATE), and Emerald Health Therapeutics Inc. (TSXV: EMH). Click the link below to view a sample of the free research report that will be available to you as a member of Active-Investors:

www.active-investors.com/registration-sg

OrganiGram Holdings Inc.

Moncton, Canada-based OrganiGram Holdings Inc.'s stock gained 11.70%, to finish Wednesday's session at $3.82 with a total volume of 6.52 million shares traded. Over the last one month and the previous three months, OrganiGram's shares have surged 23.62% and 73.64%, respectively. Furthermore, the stock has gained 17.54% in the past one year. Shares of the Company, which through its subsidiary, Organigram Inc., produces and sells medical marijuana in Canada, are trading above its 50-day and 200-day moving averages. OrganiGram Holdings' 50-day moving average of $3.22 is above its 200-day moving average of $2.61. View the research report on OGI.V at:

www.active-investors.com/registration-sg/?symbol=OGI

IntelGenx Technologies Corp.

On Wednesday, shares in Saint-Laurent, Canada headquartered IntelGenx Technologies Corp. recorded a trading volume of 81,325 shares, which was higher than their three months average volume of 16,984 shares. The stock ended the day 6.74% lower at $0.83. Shares of the Company, which develops novel oral immediate-release and controlled-release products for the pharmaceutical market, are trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $0.99 is above its 50-day moving average of $0.93. Get the free report on IGX.V at:

www.active-investors.com/registration-sg/?symbol=IGX

Antibe Therapeutics Inc.

On Wednesday, shares in Toronto, Canada headquartered Antibe Therapeutics Inc. ended the session 6.25% lower at $0.15 with a total volume of 516,515 shares traded. Antibe Therapeutics' shares have surged 57.89% in the last one month and 66.67% in the previous three months. Shares of the Company, which together with its subsidiaries, originates, develops, and out-licenses patent protected pharmaceuticals primarily in Canada, Europe, and the US, are trading above its 50-day and 200-day moving averages. Furthermore, the stock's 50-day moving average of $0.10 is greater than its 200-day moving average of $0.09. Access the most recent report coverage on ATE.V at:

www.active-investors.com/registration-sg/?symbol=ATE

Emerald Health Therapeutics Inc.

Victoria, Canada headquartered Emerald Health Therapeutics Inc.'s stock closed the day 10.66% higher at $4.05. The stock recorded a trading volume of 6.84 million shares, which was above its three months average volume of 993,565 shares. Emerald Health Therapeutics' shares have rallied 135.47% in the last one month, 258.41% in the past three months, and 251.92% in the previous one year. Shares of the Company, which together with its subsidiaries, produces and sells medical marihuana and cannabis oils in Canada, are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $2.09 is greater than its 200-day moving average of $1.62. Today's complimentary report on EMH.V can be accessed at:

www.active-investors.com/registration-sg/?symbol=EMH

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 483772

Source URL: https://marketersmedia.com/research-reports-on-organigram-holdings-intelgenx-technologies-antibe-therapeutics-and-emerald-health-therapeutics/275002

Source: AccessWire

Release ID: 275002

Latest Releases

Our Client

Subscribe and Recieve exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2017 MarketersMedia – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).